Home/Pipeline/ABD-0171

ABD-0171

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Advanced Biodesign

About Advanced Biodesign

Advanced BioDesign is a French biotech founded in 2010 with a mission to treat chemotherapy-resistant cancers by targeting the ALDH1 enzyme family, a key driver of tumor drug resistance and immunomodulation. The company has progressed its lead small-molecule inhibitor, ABD-3001, into clinical trials for AML and has a promising pre-clinical pipeline for solid tumors. Its integrated strategy combines therapeutic inhibitors with a companion diagnostic, ALDESCREEN®, aiming to personalize treatment and improve outcomes for patients with resistant cancers.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active